<DOC>
	<DOCNO>NCT00187122</DOCNO>
	<brief_summary>The main purpose study determine feasible administer intensify , multi-agent chemotherapy regimen child stage III IV non-Hodgkin lymphoma find toxicity .</brief_summary>
	<brief_title>Treatment Patients With Stage III IV Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>The overall objective research study determine toxicity feasibility administration intensify , multi-agent chemotherapy regimen child stage III IV non-Hodgkin lymphoma ( NHL ) , lymphoblastic histiotype . The planned pilot therapy include major modification best previous treatment patient T-cell acute lymphoblastic leukemia ( ALL ) may improve disease-free survival child adolescent . Ultimately , intend propose therapy evaluation set patient population large enough evaluate efficacy . Secondary objective : - To determine toxicity high-dose methotrexate ( HDMTX ) give prior induction/consolidation phase therapy repeat induction treatment ( week 16-21 ) patient advanced stage NHL , lymphoblastic histiotype . - To determine toxicity feasibility administration continuation therapy include additional drug pair use St. Jude Total XI-ALL study . - To estimate complete response ( CR ) rate event-free survival ( EFS ) child stage III/IV lymphoblastic NHL treatment intensify multiagent chemotherapy . Pooling data study gain treatment patient T-ALL Total XIII XIII B study , appropriate stratification , facilitate aim . - To compare plasma cerebrospinal fluid concentration VP-16 1 hour administration . The data obtain pool analysis Total XIII Total XIII B study - To assess serially whether frequency specific HPRT mutation related cumulative dose etoposide , plasma AUC etoposide , etoposide catechol , - To assess degree bone marrow infiltration time diagnosis serially remission use compare morphologic , immunologic molecular method . In absence morphologically detect tumor cell , estimate frequency minimal residual disease ( MRD ) remission use immunologic molecular method . The data obtain pooled analysis obtain T-cell ALL case treat Total XIII Total XIII B ALL study . - Because similar study conduct patient T-ALL Total XIII Total XIII B ALL study , pool data present study T-cell ALL case treat Total XIII Total XIII B ALL study correlate detection lymphoblast bone marrow cerebrospinal fluid ( CSF ) subsequent clinical course ( complete remission duration ) . - To evaluate sensitivity neoplastic cell diagnosis anticancer drug . This evaluation limit patient bone marrow involvement viable tumor sample diagnosis . Information obtain aim complement obtain patient T-ALL Total XIII Total XIII B ALL study . Details Treatment Plan : Pre-Induction Chemotherapy Methotrexate 200 mg/m2/hr IV push , 800 mg/m2 IV 24 hour Induction Induction Chemotherapy use several chemotherapy drug kill cancer cell body last 6 8 week . Prednisone 40 mg/m2/day PO , day 1-29 , Vincristine 1.5 mg/m2/week IV , day 1 , 8 , 15 , 22 , Daunomycin 25 mg/m2/week IV , day 1 , 8 , L-asparaginase 10,000 Units/m2 IM day 2 , 4 , 6 , 8 Etoposide 300 mg/m2 IV Days 22 , 25 , 29 , Cytarabine 300 mg/m2 IV Days 22 , 25 , 29 For infant le 12 month age , Vincristine dosage 0.05 mg/kg/dose . CNS Therapy All patient receive triple IT therapy day 1 , 22 , 43 . Patients know CNS disease receive additional IT treatments 2 consecutive CSF study normal . Children cranial nerve palsy receive local irradiation base skull . Consolidation : HDMTX 2 g/m2 day 44 51 . Mercaptopurine 75 mg/m2 PO daily , 14 day . ITMHA give spinal fluid ( IT ) day first HDMTX dose . Continuation Continuation : Continuation therapy last 120 week . The following drug give different two-drug combination treatment : Weeks : 1 VP-16 + Cyclo , 2* 6-MP + MTX , 3 MTX + Ara-C , 4 Dex + VCR , 5 VP-16 + Cyclo , 6 6-MP + HDMTX , 7 VP-16 + Ara-C , 8 Dex + VCR 9 VP-16 + Cyclo , 10 6-MP + MTX , 11 MTX + Ara-C , 12 Dex + VCR , 13 VP-16 + Cyclo , 14* 6-MP + HDMTX , 15 VP-16 + Ara-C IT MHA ( MTX , hydrocortisone , Ara-C , dose age dependent , give one day HDMTX . IT MHA ( every 4 week ) patient CNS 2 3 status . Reinduction therapy ( initial induction treatment , except one dose VP-16/ara-C give day 22 ) give week 16 21 . Dosages , Schedules Routes VP-16 : 300 mg/m2 IV 1 hour ; week , Cyclophosphamide : 300 mg/m2 IV push ; week , Mercaptopurine ( 6-MP ) : 75 mg/m2 PO ; daily x 7 , Methotrexate ( MTX ) : 40 mg/m2 IM IV week ; IM CNS radiation , Cytarabine ( Ara-C ) 300 mg/M2 IV push ; week , Dexamethasone ( Dex ) : 8 mg/m2 PO ; 3 divide dos daily x 7 , Vincristine ( VCR ) 1.5 mg/m2 IV ; week ( max 2 mg ) L-Asparaginase , ( L-ASP ) : 10,000 U/m2 IM ; every 4 week x 9 , HDMTX : 2 g/m2 IV 2 hour ; every 8 week x 7 ( leucovorin rescue use consolidation phase )</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Stage III IV Lymphoblastic Lymphoma One week less prior therapy , include steroid , vinca alkaloid , emergency radiation therapy mediastinum severe respiratory . Exclusion criterion : Patients superior vena cava syndrome , significant compression trachea require 40 % oxygen significant dyspnea normal activity</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Non-Hodgkin</keyword>
	<keyword>Lymphoma</keyword>
</DOC>